 JENA, Germany, Sept. 08, 2021 GLOBE NEWSWIRE -- InflaRx N.V. Nasdaq: IFRX, a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces its plan to proceed with a pivotal development program for vilobelimab in Hidradenitis Suppurativa HS after a successful Type A meeting with the US Food and Drug Administration FDA and receipt of the official meeting minutes. 